Overview


According to FutureWise analysis, the market for Age Related Macular Degeneration Drug is estimated to be US$ 11.29 billion in 2023 and is expected to reach US$ 19.57 billion by 2031 at a CAGR of 7.1% over the forecast period of 2023-2031.

Age-related macular degeneration (AMD) is a significant eye disease affecting older adults, which blurred central vision due to damage to the macula, a crucial part of the retina. The macula is a specialized area of the retina that processes detailed visual information. Dry AMD (also known as atrophic AMD) and wet AMD (advanced neovascular AMD) are the two types of AMD. Dry AMD can be seen in most cases and is characterized by progressive macular thinning due to aging. This type of AMD progresses through three distinct stages: early, intermediate, and late. Wet AMD is seen rarely but is a more aggressive form of the condition, usually resulting in more rapid vision loss. It occurs exclusively in the late stage and can develop from any location of dry AMD. There is significant growth of abnormal blood vessels seen in the back of the eye, which can cause substantial damage to the macula and is a characteristic of dry AMD. 

Treatment options are seen based on the type and stage of the disease. No specific treatment exists for early AMD, and regular eye exams are crucial for monitoring. Practicing a healthy lifestyle, including a balanced diet, regular exercise, and quitting smoking, can be beneficial. If an individual has intermediate AMD in one or both eyes, special dietary supplements containing vitamins and minerals may be recommended to prevent its progression to late AMD. These supplements may also be beneficial for slowing down the advancement of AMD in the other eye if late AMD is present in only one eye. For individuals with wet AMD, targeted treatments are available to halt further vision loss potentially. These include administering anti-VEGF drugs through eye injections and photodynamic therapy (PDT), which combines injections with laser treatment.

FutureWise Market Research has published a report that provides an insightful analysis of Age-Related Macular Degeneration Drug Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Age Related Macular Degeneration Drug Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • F.Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG
  • Pfizer Inc
  • Bausch Health Companies Inc
  • Regeneron Pharmaceuticals Inc
  • Amgen Inc
  • Biogen
  • Samsung Bioepis

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Age Related Macular Degeneration Drug Market:

  • In November 2022, IVERIC Bio, Inc. initiated the submission of the first portion of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a rolling review of avacincaptad pegol, a pioneering investigational inhibitor of complement C5, intended for treating geographic atrophy (GA) resulting from Age-Related Macular Degeneration (AMD).

On the driver side, an increase in the aging population globally is a significant factor. AMD is primarily an age-related condition and can be manifested in the number of elderly individuals with its high prevalence. Technological advancement with the improved diagnostic tools and techniques for early detection of the disease and monitoring of the AMD contribute to the market growth. Ongoing research and development in the fields of ophthalmology and the awareness created by the government initiatives by organizing the camps and providing free eye checkups are allowing the market growth to propel in a better way.

However, certain restraints are hampering the market growth. Limited treatment availability is one of them, where no treatment is available in some cases of dry AMD. High treatment costs due to the expensive injections and medications such as anti-VEGF injections can limit the accessibility for specific patient populations, particularly in remote areas with limited healthcare resources, hampering the market growth. Some regulatory hurdles can be seen where restrictions are created to approve the new treatments, which are lengthy and rigorous. Regulatory requirements and executing safe and effective new therapies can be a challenge for companies in the AMD market, hence restraining the market growth.

By Product Type

  • Eylea
  • Lucentis
  • Beovu
  • Others

By Disease Type

  • Dry AMD
  • Wet AMD

By Distribution Channel

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

\By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for the largest market share due to the upsurge in the prevalence of this disease, the increased burden of the geriatric population, and the increase in the research and development activities in this region. In addition, government initiatives are playing a significant role in raising funds and promoting advanced healthcare technologies; recent product launches, an increase in research partnerships, and a rise in cases of age-related macular degeneration are projected to boost the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the of Age-Related Macular Degeneration Drug Market By Product Type, By Application, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Global Age Related Macular Degeneration Drug Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Age Related Macular Degeneration Drug Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.  Global Age Related Macular Degeneration Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.   Global Age Related Macular Degeneration Drug Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Eylea
        2. Lucentis
        3. Beovu
        4. Others

  • 8.   Global Age Related Macular Degeneration Drug Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Dry AMD
        2. Wet AMD

  • 9.  Global Age Related Macular Degeneration Drug Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Specialty Pharmacy
        3. Online Pharmacy

  • 10.   North America Age Related Macular Degeneration Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Age Related Macular Degeneration Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Age Related Macular Degeneration Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Age Related Macular Degeneration Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Age Related Macular Degeneration Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F.Hoffmann-La Roche Ltd
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bausch Health Companies Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Regeneron Pharmaceuticals Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Amgen Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Biogen
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Samsung Bioepis
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients